Cannabis Report
Home > Boards > US OTC > Cannabis >

CV Sciences Inc. (CVSI)

CVSI RSS Feed
Add CVSI Price Alert      Hide Sticky   Hide Intro
Moderator: AsiaT, PennystockID2017, ANIA77, Sunblazers, Kswies, Benjamin Wulf
Search This Board: 
Last Post: 9/21/2018 9:39:20 AM - Followers: 489 - Board type: Free - Posts Today: 38

CV Sciences United States OTCMKTS:CVSI Business Cannabidiol - united states

CV Sciences, Inc., incorporated on July 26, 2013, is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

 

The Company's product candidates utilize synthetic CBD as the active pharmaceutical ingredient. Its product candidates are in preclinical studies. The Company manufactures, markets and sells products containing hemp-derived CBD primarily under its PlusCBD brand. The Company's subsidiaries include US Hemp Oil, LLC, CannaVest Laboratories, LLC, Plus CBD, LLC and CannaVest Europe, GmbH.

The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.

 

CV Sciences, Inc. Issues Letter to Shareholders

 
GlobeNewswireJune 27, 2018
 
 

LAS VEGAS, June 27, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it has issued a letter to its shareholders, providing an update on the Company’s recent progress and upcoming objectives. 

Highlights of the Letter Include:

  • Summary of its record breaking and profitable first quarter of 2018 which included record revenue, gross profit, cash flow, adjusted EBITDA and net income.
     
    Expansion of the Company’s footprint in the CBD product market with its PlusCBD Oil™ hemp-based CBD products rated #1 in the natural products retailer sales channel.  This market opportunity is forecasted at $2.5 billion by 2022.
     
    Updates on its drug development efforts, its proprietary patent-pending drug candidate (CVSI-007) to treat smokeless tobacco addiction, a $2 billion market opportunity.
     
    Corporate developments that include deleveraging the Company’s balance sheet and positioning for future growth.
     
    Details of CV Sciences’ upcoming annual general meeting (AGM) to be held on August 4, 2018 at the Company’s new San Diego headquarters.
     
    Initiatives for 2018, focusing on operational efficiencies, sales growth, distribution channels, large drug development milestones that include investigational new drug application submission and clinical trials, and uplisting our stock to a major national exchange.

The Company’s Chief Executive Officer, Joseph Dowling, commented, “Our uplist initiative to a major national exchange is an important Company objective. The national exchanges require that a listed company’s stock price trade at certain levels for acceptance. We have included a proposal for shareholder vote at our AGM on August 4, 2018 for a reverse stock split, which has as its sole purpose clearing a pathway for the Company to “uplist” to a major national exchange. The Company will effectuate the reverse split only in connection with an application to uplist to a major exchange, and only if necessary.”  

To read the Letter to Shareholders in full, please visit: https://ir.cvsciences.com

About CV Sciences, Inc.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

 

The Company competes with GW Pharmaceuticals, PLC, Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc

 

CV Sciences, Inc. Announces Landmark Publication on the Toxicology and Safety Assessment of Base Material of its PlusCBD Oil™ Products

 
GlobeNewswireJune 15, 2018
 
 

LAS VEGAS, June 15, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today the June 7, 2018 publication of the toxicology and safety results of an extract from the base raw materials used in its market leading PlusCBD Oil™ consumer products. The Company contracted respected scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the battery of toxicological studies to investigate the safety of oral consumption of the Company’s hemp cannabidiol (CBD) oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion.

The monumental study entitled, “An Assessment of the Genotoxicity and Subchronic Toxicity of a Subcritical Fluid Extract of the Aerial Parts of Hemp”concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic. The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al.’s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil. The battery of GLP/OECD compliant studies is a major contribution in advancement of the science of hemp-derived CBD.

The investment in this toxicological assessment demonstrates CV Sciences’ commitment in furthering the science behind the ingredient. AIBMR’s Chief Scientific Officer, John Endres, ND, comments, “Until today, there have been no comprehensive toxicological safety assessments completed on hemp CBD oil for 38 years. The completion and publication of these safety studies on this ingredient in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”

The Company’s Chief Executive Officer, Joseph Dowling, echoed this sentiment. “We are thrilled to advance phytocannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS status,” he remarked. “As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all hemp extract manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”

About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Video tour of San Diego Office of CVSI.
https://www.facebook.com/pluscbdoil/videos/1974202205985123/

Cannabis Report
CVSI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#26373  Sticky Note CRITICAL INFO ON PATENTS: Deetew 09/14/18 08:34:18 PM
#25394  Sticky Note CV Sciences, Inc. Achieves Industry’s First Hemp Extract Kswies 09/10/18 07:58:31 PM
#20309  Sticky Note Please read this BOARD WARNING before you submit IH Admin [Tisha] 08/22/18 12:47:06 PM
#27471   Back in today at $5.22, $CVSI Chartmaster 09/21/18 09:39:20 AM
#27470   agian at $ 9.50 thats it Mark44 09/21/18 09:36:58 AM
#27469   Shorted more $ 8.50 and $ 6.94 = Mark44 09/21/18 09:32:14 AM
#27468   wrong. tlry sellers will come here. with coming chilling 09/21/18 09:24:16 AM
#27467   Bid up nicely premarket... lets hope it holds... DropLine 09/21/18 09:22:53 AM
#27466   or not. chilling 09/21/18 09:21:21 AM
#27465   or not. chilling 09/21/18 09:21:19 AM
#27464   Need the market to correct so hopefully it johnnyo417 09/21/18 09:08:15 AM
#27463   Premarkets dont look so good for our neighbors CashMoneyCarl 09/21/18 08:58:21 AM
#27462   These discussions over hemp and marijuana and their BidnessMan 09/21/18 08:40:33 AM
#27461   Good Morning to all! The excitement of owning gman23 09/21/18 08:37:58 AM
#27459   This is a huge reason why we are CashMoneyCarl 09/21/18 07:48:56 AM
#27458   Does any one have any info re what Mark44 09/21/18 07:47:38 AM
#27457   The end of q numbers should be strong, Mark44 09/21/18 07:42:40 AM
#27456   NECT CATALYSTS:Hemp Act—>Uplist—>Q3(nov)! canncan 09/21/18 06:42:08 AM
#27455   “It’s become a big market” and “customers rushed ravens723 09/21/18 06:38:39 AM
#27454   http://www.indeonline.com/news/20180921/confusion-remains-over-cbd-oil-sales Sunblazers 09/21/18 06:29:18 AM
#27452   My Short will double poss triple if these Mark44 09/21/18 05:27:55 AM
#27449   Thanks chilling! So it’s general hearsay. Either way, playofthedivine 09/21/18 05:17:25 AM
#27448   They have awesome products. lester12483 09/21/18 04:19:41 AM
#27444   I am ready to buy more dipping below IrinaNewInTown 09/21/18 12:59:24 AM
#27443   I sense a pitiful paycheck for work that IrinaNewInTown 09/21/18 12:55:19 AM
#27442   wow, I watched some of those so, maybe ap17 09/21/18 12:47:56 AM
#27440   You are absolutely right . There are substances, Chirodoctor 09/21/18 12:43:43 AM
#27439   He will key in just about anything at MaxwellE 09/21/18 12:39:00 AM
#27438   Nice tank you have the M1A1 Panzer 09/21/18 12:23:08 AM
#27437   CVSI Has Higher quarterly revenues than TLRY............The NASDAQ AD2000 09/21/18 12:20:19 AM
#27435   CVSI lost some respect, hopefully will recover rancher64 09/21/18 12:06:07 AM
#27434   tell us more iglow Ilbedem 09/21/18 12:04:24 AM
#27433   I sense jealousy & fear in IG. canncan 09/20/18 11:56:17 PM
#27432   Through twitter, could be NASDAQ, ring the bell ali12 09/20/18 11:40:06 PM
#27431   LOLOL! No one but OTCM noobie investors believe I-Glow 09/20/18 11:38:21 PM
#27430   If they did get Nasdaq*ed now, would Alwaysbmikki 09/20/18 11:33:12 PM
#27429   Prove that Mona's still calling the shots. Deetew 09/20/18 11:32:54 PM
#27428   What's the source of the NY trip? Deetew 09/20/18 11:30:46 PM
#27427   IG David, you are too funny. canncan 09/20/18 11:27:12 PM
#27426   Uplist? Damn that is too funny - Mona/CVSI I-Glow 09/20/18 11:26:23 PM
#27425   Uplist...is coming soon.All the subtle signs are there. canncan 09/20/18 11:19:51 PM
#27424   another poster dropped by cvsi in san diego. chilling 09/20/18 11:19:16 PM
#27423   Why has Mona committed more securities/accounting fraud? Such I-Glow 09/20/18 11:15:33 PM
#27422   Hi playofthedivine, I know your not asking me ali12 09/20/18 11:11:20 PM
#27421   The story of cannabis criminalization is convoluted. There's Deetew 09/20/18 11:03:30 PM
#27420   ap17, CashMoney & others: thanks for your insights playofthedivine 09/20/18 11:02:26 PM
#27419   Keep it simple now, soy bean tariffs have ali12 09/20/18 10:58:47 PM
#27418   It's more than just big pharma, big oil, Deetew 09/20/18 10:45:16 PM
#27417   * * $CVSI Video Chart 09-20-18 * * ClayTrader 09/20/18 10:43:16 PM
#27416   $6.50 + run tomorrow get your shares early. AD2000 09/20/18 10:24:10 PM
#27415   Yes, much thx. Went on a $5.oo per MaxwellE 09/20/18 10:19:22 PM
#27414   Someone posted on here about 2 weeks ago AsiaT 09/20/18 10:18:44 PM
#27413   AsiaT or others. How did you find playofthedivine 09/20/18 10:16:45 PM
PostSubject